Adoptive immunotherapy with antitumor T cells is a promising novel approach for the treatment of cancer. However, T-cell therapy may be limited by the cotransfer of regulatory T cells (T reg 
Introduction
Immunotherapy for cancer has included nonspecific stimulation of the immune system, active immunization with tumor-specific antigens, and adoptive cell therapy-the transfer of tumor-specific T cells. We have investigated adoptive cell therapy for treating lymphoma (1, 2) . Historically, adoptive cell therapy for cancer has focused on isolating and expanding populations of T cells that have direct cytotoxic effects on tumors (3) (4) (5) (6) . We use active immunization to generate antitumor T cells in vivo and transfer these T cells into lymphodepleted recipient mice. The efficacy of this maneuver is impressive and cures large tumors (1, 2) . Specifically, our early work showed that CD8 T-cell antitumor immunity can be induced by the combination of cytotoxic chemotherapy with local, intratumoral injection of CpG (1, 7) . Recently, we have extended the use of CpG as an immunotherapy by exposing tumor B cells to CpG ex vivo and subsequently injecting them into the host as a whole-tumor cell vaccine (2) . This approach obviates the need for an accessible, injectable, tumor site. Importantly, vaccination with such CpG-loaded tumor B cells induces a tumor-specific CD4 and not CD8 T-cell response. Relatively small numbers of these CD4 T cells were sufficient to cure large and established lymphoma tumors.
This and other recent reports have suggested that CD4 T cells can be effective in adoptive immunotherapy (2, (8) (9) (10) (11) . However, a relevant concern in using CD4 T cells for adoptive therapy is the potential for cotransfer of regulatory T cells (T reg ). Here, we have identified 2 surface markers-CD44 and CD137-that can be used to isolate a population of antitumor CD4 T cells while excluding a population of inhibitory T regs . Adoptive transfer of CD137 neg CD44 hi CD4 T cells provided significant protection from B-cell lymphoma. CD137 pos CD44 hi CD4 T cells were predominantly T regs and suppressed both effector cell proliferation and antitumor activity.
Materials and Methods

Reagents
CpG 1826 with sequence 5 0 -TCCATGACGTTCCTGACGTT was provided by Coley Pharmaceutical Group (Ottawa, Canada). Fluorescein isothiocyanate-conjugated CpG 1826 was purchased from InvivoGen. The following monoclonal antibodies (mAb) were used for flow cytometry: antimouse CD3, anti-mouse CD4, anti-mouse CD8, anti-mouse CD44, anti-mouse CD137, anti-mouse IFN-g, anti-mouse CD25, anti-mouse FoxP3, anti-mouse CD62L, anti-mouse CCR7, antimouse CD103, anti-mouse CD69, anti-mouse GITR, anti-mouse Thy1.1, anti-mouse CD45.1, anti-human CD3, anti-human CD4, anti-human CD8, anti-human CD45RO, anti-human CD137, anti-human CD25, anti-human FoxP3, and isotype control. Antibodies were purchased from either Becton Dickinson (BD) Biosciences or eBioscience.
Cell lines and mice
H11 is a pre-B cell line in the C57BL/6 background generated as follows: primary bone marrow cells were isolated from C57BL/6 mice and infected with the retrovirus vector MSCV-neo/p190Bcr-Abl, which carries the oncogene Bcr-Abl (12; a gift from Drs. M. Cleary and K. Smith, Stanford School of Medicine). Tumor cells were cultured in complete RPMI 1640 (cRPMI) medium (Invitrogen Life Technologies) containing 10% fetal calf serum (Thermo Scientific), 100 U/mL penicillin, 100 mg/mL streptomycin (both from Invitrogen Life Technologies), and 50 mmol/L 2-ME (Sigma-Aldrich). This cell line was previously used in studies from our laboratory (2) and was tested for uniformity of cell-surface markers (B220 pos CD43
neg IgM neg IgD neg ) by fluorescence-activated cell sorting (FACS). Six-to 8-week-old female Thy1.1, CD45.1, and wild-type C57BL/6J mice were purchased from Jackson Laboratories. All studies were approved by the Stanford Administrative Panel on Laboratory Animal Care.
Tumor inoculation and animal studies
H11 tumor cells were incubated in the presence of 3 mg/mL of CpG at 37 C and 5% CO 2 . As shown previously, CpG is taken up by H11 cells during this incubation (2) . After 24 hours, cells were vigorously washed 3 times with wash buffer to remove any unbound, residual CpG. H11 cells that were loaded with CpG (CpG/H11) were irradiated at 50 Gy and used to vaccinate C57BL/6 donor mice s.c. for 5 consecutive days. On day 13, bone marrow and splenocytes of donor mice were transferred by i.v. injection into irradiated C57BL/6 recipient mice (9.5Gy TBI, Phillips x-ray unit, 250 kV, 15 mA) along with 1 Â 10 6 irradiated CpG/H11 tumor cells as a posttransplant "booster" vaccine that was prepared in the same fashion as above (1) . In studies using congenic donors, transferred bone marrow was from wild-type, noncongenic mice to allow precise tracking of transplanted donor cells. Recipient mice were challenged with H11 tumor cells s.c. at a dose of 1 Â 10 7 cells in 50 mL of serumfree RPMI on day 16. Tumor growth was monitored by caliper measurement (Fig. 1A) .
In vitro assays
IFN-g production assay. Peripheral blood mononuclear cells (PBMC) were collected from tail vein, anticoagulated with 2 mmol/L ethylenediaminetetraacetic acid in PBS, then diluted 1:1 with Dextran T500 (Pharmacosmos) 2% in PBS and incubated at 37 C for 45 minutes to precipitate red cells. Leukocyte-containing supernatant was removed and centrifuged, and remaining red cells were lysed with ammonium chloride potassium buffer (Quality Biological). PBMCs were then cocultured with 1 Â 10 6 irradiated H11 cells for 24 hours with 0.5 mg anti-mouse CD28mAb (BD PharMingen) and in the presence of monensin (Golgistop; BD Biosciences) for the last 5 hours at 37 C and 5% CO 2 . Intracellular IFN-g expression was assessed with BD Cytofix/Cytoperm Plus Kit per instructions.
T reg suppression assay. CD137 pos and CD137 neg cell populations were isolated by FACS and mixed at various ratios in a 96-well round bottom plate. Cells were stimulated in with equal numbers of polystyrene latex beads (Interfacial Dynamics) coated with 1.0 mg/mL anti-CD3 (145-2C11; eBioscience) and 0.5 mg/mL anti-CD28 (37.51; eBioscience). Cells were pulsed with 1 mCi of methyl-[ 3 H]thymidine (Amersham Biosciences) for 6 hours during the last 72 hours of stimulation and harvested onto filters (Wallac). Filters were wetted with Betaplate scintillation fluid (PerkinElmer) and counts per minute read on a 1205 Betaplate liquid scintillation counter (Wallac).
Flow cytometry
Cells were surface stained in wash buffer (PBS, 1% FBS, and 0.01% sodium azide), fixed in 2% paraformaldehyde and analyzed by flow cytometry on a BD FACS Calibur, LSR II, or FACS Aria System. Data were analyzed with Cytobank (13) . Flowcytometric cell sorting was used to purify T-cell subsets from splenocytes of CpG/H11-vaccinated mice.
Primary human lymphoma specimens
Tumor specimens were obtained with informed consent in accordance with the Declaration of Helsinki and with approval by Stanford University's Administrative Panels on Human Subjects in Medical Research. Samples were transferred directly from the operating room to the laboratory and used for the preparation of viable, sterile single-cell suspensions. Lymph node tissue was disaggregated, filtered through a metal sieve, washed, resuspended in media composed of 90% FBS (HyClone) and 10% dimethyl sulfoxide (Sigma), frozen slowly in the vapor phase of liquid nitrogen in multiple cryotubes, and stored in liquid nitrogen. PBMCs from healthy individuals were isolated with density gradient separation Ficoll-Paque PLUS (Amersham Biosciences) and subsequently stained with antibodies from Becton Dickinson or eBioscience as above.
Statistical analysis
Prism software (GraphPad) was used to analyze tumor growth and determine statistical significance of differences between groups by applying an unpaired Student t test. P < 0.05 were considered significant.
Results
Vaccine-induced CD4 T cells are necessary and sufficient for tumor rejection
We have developed a model for adoptive cell therapy of lymphoma whereby antitumor T cells are generated in vivo through vaccination with a CpG-loaded whole-cell vaccine (CpG/H11; ref.
2). These vaccine-induced cells are tumor specific and cure large and established tumors when isolated and transferred into lethally irradiated, syngeneic recipient mice (2) . We investigated whether a specific subset of CD4 T cells was tumor reactive. CD4 or CD8 T-cell subsets were negatively isolated from CpG/H11-vaccinated, Thy1.1 congenic, donor mice. These purified subsets were transferred into lethally irradiated, Thy1.2 congenic recipients. Three days posttransfer, recipients were challenged s.c. with 1 Â 10 7 H11
tumor cells (Fig. 1A) . Purified CD4 T cells from vaccinated donors were sufficient to protect 80% of recipient mice for more than 50 days (Fig. 1B) . Conversely, purified CD8 T cells were comparable with splenocytes from unvaccinated donors and had no effect on tumor growth rate. We investigated the mechanism for CD4-mediated tumor cell killing. As we described previously, the H11 tumor cell line is MHC class II negative, therefore CD4 T cells cannot kill tumor cells directly (2) . We tested the role of other effector cell populations by treating recipient mice with purified CD4 T cells plus a depleting antibody for natural killer (NK) cells (anti-NK1.1), CD8 T cells (anti-CD8), or a blocking antibody against IFN-g (anti-IFN-g). Depletion of NK cells and CD8 T cells were confirmed by flow cytometry. Three days posttransfer, recipients were challenged s.c. with 1 Â 10 7 H11 tumor cells. Depletion of NK cells had no effect on tumor rejection. However, depletion of CD8 T cells resulted in late relapses with tumors beginning to grow 20 days after tumor challenge. Blockade of IFN-g eliminated the antitumor effect in 6 of 10 recipient mice (Fig. 1C) . Reconstitution of the endogenous, Figure 1 . Vaccine-induced CD4 T cells are necessary and sufficient for tumor rejection. A, vaccination and adoptive therapy schema. B, recipient mice received purified CD4 or CD8 T cells from vaccinated donor mice or complete splenocytes from unvaccinated donor mice. Arrow indicates day of tumor challenge. C, recipient mice received purified CD4 T cells as above and were treated with depleting antibodies. Recipient mice were followed for tumor growth (n; 10 mice per group). D, PBLs were isolated from recipient mice 10 days after transfer and assayed for IFN-g production. Plots are representative of 3 independent samples per group. N/A, only T cells of the transferred subset were present in recipient mice.
host CD8 T cell compartment can be observed as early as 10 days posttransplant ( Supplementary Fig. S1 ), these results suggest that CD4-mediated IFN-g production is a critical early mediator in inducing a host CD8 T-cell response that is ultimately necessary for lasting tumor rejection.
Antitumor immune responses in the recipient mice were analyzed 15 days after transfer. Phenotypic fidelity of the transferred T-cell subsets was confirmed and donor-derived cells (identified by expression of the Thy1.1 marker) were more than 99% pure populations of either CD4 or CD8 T cells (Supplementary Fig. S2 ). Previously, we showed that CD4 antitumor immune responses were tumor specific (2) . Here, we evaluated by in vitro IFN-g production assay whether tumor reactivity was limited to donor cells. Whole peripheral blood lymphocytes (PBL) from recipient mice were collected, placed in coculture with irradiated tumor cells, and IFN-g production was measured by intracellular flow cytometry. Using the Thy1.1 marker, we were able to distinguish whether donorderived recipient cells (Thy1. (Fig. 1D) . Conversely, only 0.6% of donor-derived (Thy1.1 pos ) CD8 T cells were IFN-g pos . Because it has been reported that homeostatic proliferation induces a memory phenotype in transferred T cells (14, 15) , we assayed for CD44 expression on tumor-reactive CD4 and CD8 T cells in an in vitro IFN-g production assay. CD44, the hyaluronic acid receptor, identifies antigen-experienced CD4 T cells (16) . In recipients transplanted with vaccine-induced T cells, there was evident increased expression of CD44, specifically among the IFN-g producing, donor T cells (Fig.  1D ). This suggested that expression of CD44 might serve as one potential marker for the identification and eventual isolation of a tumor-reactive subset of CD4 T cells.
CD137
pos CD44 hi CD4 T cells are expanded in vaccinated donor mice
We sought to identify the CD4 T cell subset necessary for mediating antitumor immune responses. We compared vaccinated and unvaccinated donor mice for expression of memory and activation markers including CD44, CD62L, and CCR7 (14-18). CD44 expression was increased on CD4 T cells in vaccinated mice. However, we observed no differences between vaccinated and unvaccinated mice in any of the other markers or combinations thereof (Supplementary Fig. S3 ).
When comparing expression of CD137 in vaccinated and unvaccinated donor mice, we observed a distinct increase in the expression of CD137 on CD4 T cells in vaccinated animals (Fig. 2) . The CD137 pos population was predominantly within the CD44 hi subset, similar to IFN-g-producing cells shown in Fig. 1 . Based on these observations, we initially hypothesized that CD137 expression on CD4 T cells in vaccinated mice may identify a tumor reactive population. To further support this hypothesis, studies have shown that CD137 is an activation marker on many immune cell types including CD4 and CD8 T cells, B cells, NK cells, NK-T cells, monocytes, neutrophils, and dendritic cells (19) . On CD8 T cells, binding of CD137 leads to proliferation, cytokine production, functional maturation, and prolonged survival (19) . Recent work from our group and others has shown that agonistic mAbs against CD137 (4-1BB) can provoke CD8 T-cell antitumor responses capable of eradicating established tumors in a range of murine tumor models (20) (21) (22) .
CD137 identifies a population of activated T regs
We characterized the population of CD137 pos CD4 T cells further and analyzed whole splenocytes from vaccinated and unvaccinated donor mice for expression of CD44, CD137, and FoxP3. As expected, FoxP3 staining identified the natural physiologic ratio of approximately 5% to 15% of CD4 T cells as T regs in donor mice (23) . Surprisingly, in vaccinated mice, CD137 expression marked more than 65% of this T reg population. Conversely, in unvaccinated donors or donors vaccinated with CpG alone, CD137 identified less than 35% of T regs ( Fig. 3A and Supplementary Fig. S4 ). Therefore, in the context of our vaccination, CD137 identifies an expanded subset of FoxP3 pos CD4 T cells. We compared CD137 pos and CD137 neg T regs from vaccinated donors for expression of traditional T reg markers including CD25, GITR, and CD103 as well as memory/activation markers including CD44, CD62L, and CD69 (Fig. 3B) . Compared with CD137 neg T regs , the CD137 pos subset is distinct in its expression of CD69 (high), CD44 (high), and CD62L (low). High CD69 expression suggests that these cells are more activated than their CD137 neg counterparts. The phenotype of CD44 hi CD62L low is characteristic of an effector memory population.
CD137
pos CD44 hi and CD137 neg CD44 hi CD4 T cells maintain expression of both CD137 and FoxP3 after adoptive transfer
As they seem to have an effector memory phenotype, we asked whether CD137 pos CD44 hi T regs persisted following adoptive transfer and whether they maintained expression of CD137 and FoxP3. With FACS, we isolated CD137 pos CD44 hi and CD137 neg CD44 hi CD4 T cells from vaccinated, congenic (CD45.1 pos ) donors to purity of greater than 98% (Fig. 4A ). We transferred these purified populations into lethally irradiated recipients. Ten days after transfer, recipient mice were sacrificed and splenocytes were analyzed for the presence of T cells expressing the congenic marker, CD45. 57.6% of total tumor-infiltrating T cells (Fig. 5A) (Fig. 5B, left) . Similarly, in mice receiving CD137 neg CD44 hi cells, 18.8% of splenic T cells were of donor origin (Fig. 5B, right) . Recipient bone marrow and lymph node compartments were not studied. These findings suggest that the suppressive effect of the CD137 pos population takes place in the spleen or other lymphocyte compartments but not in the tumor itself. (Fig. 6A ). To address whether this suppressive effect required cell-cell contact, we carried out a similar assay but separated CD137 pos CD44 hi and CD137 neg CD44 hi cells across a Transwell. The suppressive effect of CD137 pos CD44 hi cells was eliminated in the absence of cell-cell contact. In coculture across the Transwell, proliferation of CD137 neg CD44 hi cells was similar to controls (Fig. 6B ).
Next, we tested whether CD137 pos CD44 hi cells could suppress the antitumor response mediated by CD137 neg CD44 hi cells. Previously, when we transferred whole CD4 T cells we observed impressive tumor rejection (2; Fig. 1 pos CD44 hi cells we cotransferred, this antitumor effect was blocked and 0% of recipient mice survived longer than 20 days (Fig. 6C) . Lower numbers of CD137 pos CD44
hi cells did not inhibit tumor rejection. On day 15 after transfer, PBLs from recipient mice were collected and placed in coculture with irradiated tumor cells for 24 hours. IFN-g production was measured by intracellular flow cytometry. In mice receiving CD137 pos and CD137 neg CD44 hi cells, only 0.9% of CD4 T cells produced IFN-g (Fig. 6D) . Conversely, in recipient mice receiving CD137 neg CD44 hi cells alone, 4.7% of CD4 T cells produced IFN-g.
In human lymphoma-involved lymph nodes, CD137 identifies a population of activated T regs
Recent studies have identified cell surface markers that define a discrete subset of CD25 pos FoxP3 pos T regs preferentially expanded in patients with cancer (24) . We investigated whether our observations about CD137 in a murine tumor model were consistent in the human tumor samples. In tumor-bearing mice, we observed that a large percentage of CD137 pos CD4 T cells were present in tumor-involved spleen. This CD137 pos population was overwhelmingly CD25 pos FoxP3 pos T regs (Fig. 7A) . We examined human lymphoma biopsies for whether CD137 similarly served as a marker for CD25 pos FoxP3 pos T regs . Follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL) were analyzed by flow cytometry. A representative flow plot shows the gating strategy used to define these populations (Fig. 7B) . CD137 pos CD45RO
pos CD4 T cells were present in FL (mean ¼ 5.14% AE SEM 0.34%) and MCL (mean ¼ 8.24% AE SEM 1.68%) (Fig. 7C,  left) . As in the murine system, this CD137 pos population was predominantly CD25
pos FoxP3 pos (FL: mean ¼ 68.65% AE SEM 3.28%; CLL: mean ¼ 54.73% AE SEM 5.70%; Fig. 7C, right) . Therefore, CD137 may serve as an effective marker for CD25 pos FoxP3 pos T regs in human lymphoma patients as well.
Discussion
Our results indicate that 2 markers-CD44 and CD137-can be used to isolate a population of antitumor CD4 T cells while effectively excluding T regs . Here, we show that (i) CD137 pos CD44 hi expression defines a population of activated CD4 T regs that can suppress the proliferation of effector cells in a contact-dependent manner, (ii) the CD137 pos CD44 hi T reg population persists following adoptive transfer and can inhibit tumor rejection in vivo, and (iii) vaccination with CpG-activated lymphoma induced CD137 neg CD44 hi CD4 T cells can transfer protection from B-cell lymphoma tumor challenge.
Rosenberg and colleagues have shown impressive clinical outcomes using ex vivo generated T cells in adoptive immunotherapy for metastatic melanoma (3) (4) (5) . Our prior work established that a CpG-loaded whole-cell vaccine induced antitumor CD4 T cells that were both necessary and sufficient to adoptively transfer antitumor immunity. To date, the field of adoptive cell therapy has focused primarily on CD8 CTLs (3, 5, 6) . However, important roles for CD4 T cells in antitumor immunity have also been shown (8-11). Hunder and colleagues showed durable clinical remissions in melanoma patients treated with ex vivo expanded, antigen-specific CD4 T cells (8) . Recently, studies by Xie and colleagues (10) and Quezada and colleagues (9) have shown in a TCR transgenic model that naive tumor-specific CD4 T cells are able to induce regression of established tumors in lymphopenic hosts. Our findings support this prior body of work and suggest that antitumor CD4 T cells can be induced in vivo, isolated, and used in adoptive immunotherapy of established lymphoma tumors. Our results suggest that these antitumor CD4 T cells produce IFN-g and recruit a long-lasting antitumor response mediated by host CD8 T cells. Importantly, our work does not rule out other sources of IFN-g including, but not limited to, NKT cells.
A concern in any CD4 T cell-based therapy is the potential for contamination by T regs . This is particularly relevant to our system in which antitumor T cells are isolated following in vivo induction. Hunder and colleagues addressed this issue by selecting tumor reactive clones and expanding them ex vivo. Quezada and colleagues combined CD4 adoptive transfer with blockade of CTLA-4 to inhibit the function of T regs . These approaches have led to impressive outcomes in human melanoma and mouse melanoma tumor models, respectively. We have defined a surface marker for a population of activated pos and CD137 neg populations were isolated and transferred into lethally irradiated recipient mice (n; 5 mice per group). Mice were followed for tumor growth and overall survival. Arrow indicates day of tumor challenge. D, PBLs were isolated from recipient mice 10 days after transfer and assayed for IFN-g production following 24-hour coculture with irradiated tumor cells. Plots are representative of 3 independent samples. ÃÃ , P < 0.001; ÃÃÃ , P < 0.0001.
T regs that can facilitate their removal prior to adoptive transfer or allow their targeting with mAbs in the posttransplant recipient. Specifically, CD137 and CD44 can be used to distinguish antitumor CD4 T cells from T regs . To our knowledge, this is the first report of CD137 expression being used to distinguish these 2 populations.
Surface marker identification of T regs is not a novel pursuit and a number of studies have claimed to identify T regs by expression of surface markers including MHC-II, CD45RO/RA, CCR7, and ICOS (25) (26) (27) (28) . Most recently, Camisaschi and colleagues (24) have observed that the expression of LAG-3 on human CD4 T cells defines a discrete subset of CD25 posFoxP3 pos T regs that is preferentially expanded in patients with cancer. Although LAG-3 was not included in our evaluation of human lymphoma biopsies, we anticipate that both CD137 and LAG-3 may be complementary in identifying tumor-reactive T regs .
In summary, the work reported here shows that CD137 expression on CD4 T cells identifies a population of activated T regs that suppress proliferation and antitumor immune responses. Importantly, the combination of cell surface markers CD44 and CD137 can be used to isolate a population of antitumor CD4 T cells while excluding a large, activated subset of T regs for the purpose of adoptive immunotherapy of lymphoma
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